Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia-Reference-Cited by-同舟云学术

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Published:2020-11-02 Issue:3 Volume:62 Page:659-668
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Megías-Vericat Juan Eduardo¹²^ORCID,Martínez-Cuadrón David³⁴^ORCID,Herrero María José¹⁵,Rodríguez-Veiga Rebeca³⁴,Solana-Altabella Antonio²^ORCID,Boluda Blanca³⁴^ORCID,Ballesta-López Octavio²^ORCID,Cano Isabel³⁴,Acuña-Cruz Evelyn³⁴,Cervera José³⁴,Poveda José Luis²,Sanz MiguelÁngel³⁴^ORCID,Aliño Salvador F.¹⁵⁶,Montesinos Pau³⁴^ORCID

Affiliation:

1. Grupo de Farmacogenética, Instituto Investigación Sanitaria La Fe and Área del Medicamento, Hospital Universitari i Politècnic, Valencia, Spain

2. Servicio de Farmacia, Área del Medicamento. Hospital Universitari i Politècnic, Valencia, Spain

3. Servicio de Hematología y Hemoterapia. Hospital Universitari i Politècnic, Valencia, Spain

4. CIBERONC, Instituto Carlos III, Madrid, Spain

5. Departamento Farmacología, Facultad de Medicina, Universidad de Valencia, Valencia, Spain

6. Unidad de Farmacología Clínica, Área del Medicamento. Hospital Universitari I Politècnic, Valencia, Spain

Funder

Instituto Carlos III

Instituto Investigación Sanitaria La Fe

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1839650

Reference35 articles.

1. Pharmacogenomics and the treatment of acute myeloid leukemia

2. Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

3. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin

4. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients

5. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Significance of MRP 1 in Achieving Complete Remission Following Induction Therapy in Acute Myeloid Leukemia;Current Molecular Medicine;2024-07-09

2. Effect of single-nucleotide polymorphism in SLCO1B1 and CDA genes on response and toxicity of induction chemotherapy in acute myeloid leukemia;The Egyptian Journal of Haematology;2024-01

3. Association between genetic variants of transmembrane transporters and susceptibility to anthracycline‐induced cardiotoxicity: Current understanding and existing evidence;Clinical Genetics;2023-11-14

4. Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia;Cancer Medicine;2023-08-21

5. Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia;Cancers;2023-04-12